1. Home
  2. ASMB vs TDF Comparison

ASMB vs TDF Comparison

Compare ASMB & TDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • TDF
  • Stock Information
  • Founded
  • ASMB 2005
  • TDF 1994
  • Country
  • ASMB United States
  • TDF Singapore
  • Employees
  • ASMB N/A
  • TDF N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • TDF Finance/Investors Services
  • Sector
  • ASMB Health Care
  • TDF Finance
  • Exchange
  • ASMB Nasdaq
  • TDF Nasdaq
  • Market Cap
  • ASMB 225.9M
  • TDF 244.7M
  • IPO Year
  • ASMB 2010
  • TDF N/A
  • Fundamental
  • Price
  • ASMB $31.43
  • TDF $11.68
  • Analyst Decision
  • ASMB Strong Buy
  • TDF
  • Analyst Count
  • ASMB 5
  • TDF 0
  • Target Price
  • ASMB $44.25
  • TDF N/A
  • AVG Volume (30 Days)
  • ASMB 141.0K
  • TDF 79.2K
  • Earning Date
  • ASMB 11-07-2025
  • TDF 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • TDF N/A
  • EPS Growth
  • ASMB N/A
  • TDF N/A
  • EPS
  • ASMB N/A
  • TDF N/A
  • Revenue
  • ASMB $33,247,000.00
  • TDF N/A
  • Revenue This Year
  • ASMB $14.29
  • TDF N/A
  • Revenue Next Year
  • ASMB N/A
  • TDF N/A
  • P/E Ratio
  • ASMB N/A
  • TDF N/A
  • Revenue Growth
  • ASMB 54.77
  • TDF N/A
  • 52 Week Low
  • ASMB $7.75
  • TDF $7.15
  • 52 Week High
  • ASMB $32.44
  • TDF $10.62
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 63.80
  • TDF 56.67
  • Support Level
  • ASMB $30.00
  • TDF $10.95
  • Resistance Level
  • ASMB $31.80
  • TDF $11.57
  • Average True Range (ATR)
  • ASMB 1.64
  • TDF 0.25
  • MACD
  • ASMB 0.07
  • TDF -0.00
  • Stochastic Oscillator
  • ASMB 77.72
  • TDF 82.25

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

Share on Social Networks: